Holen Sie sich die Stockscreener-App
1.7269
2.38%
0.0469
Handel nachbörslich:
1.71
-0.0169
-0.98%
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria
Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
500: Something went wrong - Investing.com Canada
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com
galmed pharmaceuticals ltd. Earnings dates - RTTNews
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):